SCHEDULE: Farallon Capital Discloses Stake in Tyra Biosciences

Farallon Capital Management, through various affiliated entities, has reported a beneficial ownership of 6.6% of Tyra Biosciences, Inc. common stock as of March 31, 2026.

Summary

• Farallon Capital Management, via multiple limited partnerships and limited liability companies, has disclosed a beneficial ownership of 3,580,818 shares of Tyra Biosciences, Inc. common stock.
• This holding represents 6.6% of the total class of securities outstanding as of March 31, 2026.
• The filing is an amendment to a Schedule 13G, indicating a passive investment stake.
• The reporting entities include various Farallon Capital Partners, Institutional Partners, Offshore Investors, and Healthcare Partners entities, along with their respective general partners and key individual managers.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on an existing passive investment stake and does not contain operational or financial performance data.

Future Outlook

This filing is an amendment to a Schedule 13G, which is typically used for passive investors. It does not contain forward-looking statements or specific guidance regarding future performance or strategy.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Farallon Capital Management indicates a significant passive investment in Tyra Biosciences, Inc. Such filings often precede or follow shifts in institutional investor sentiment or strategic positioning within the biotechnology sector.

Stakeholder Impact

• Shareholders: The filing may influence market perception due to the significant stake held by a well-known investment firm, potentially impacting share price and trading volume.

Key Dates

Keywords

Tyra Biosciences, Farallon Capital, Schedule 13G, Beneficial Ownership, SEC Filing, Investment, Common Stock